6.
Yagi K, Akagi K, Hayashi H, Nagae G, Tsuji S, Isagawa T
. Three DNA methylation epigenotypes in human colorectal cancer. Clin Cancer Res. 2009; 16(1):21-33.
DOI: 10.1158/1078-0432.CCR-09-2006.
View
7.
Kim J, Rhee Y, Bae J, Kwon H, Cho N, Kim M
. Subsets of microsatellite-unstable colorectal cancers exhibit discordance between the CpG island methylator phenotype and MLH1 methylation status. Mod Pathol. 2013; 26(7):1013-22.
DOI: 10.1038/modpathol.2012.241.
View
8.
Daly M, Paquette I
. Surveillance, Epidemiology, and End Results (SEER) and SEER-Medicare Databases: Use in Clinical Research for Improving Colorectal Cancer Outcomes. Clin Colon Rectal Surg. 2019; 32(1):61-68.
PMC: 6327727.
DOI: 10.1055/s-0038-1673355.
View
9.
Lind G, Danielsen S, Ahlquist T, Merok M, Andresen K, Skotheim R
. Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas. Mol Cancer. 2011; 10:85.
PMC: 3166273.
DOI: 10.1186/1476-4598-10-85.
View
10.
Weisenberger D, Siegmund K, Campan M, Young J, Long T, Faasse M
. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006; 38(7):787-93.
DOI: 10.1038/ng1834.
View
11.
Aryee M, Jaffe A, Corrada-Bravo H, Ladd-Acosta C, Feinberg A, Hansen K
. Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics. 2014; 30(10):1363-9.
PMC: 4016708.
DOI: 10.1093/bioinformatics/btu049.
View
12.
Zlobec I, Bihl M, Foerster A, Rufle A, Lugli A
. Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features. J Pathol. 2011; 225(3):336-43.
DOI: 10.1002/path.2879.
View
13.
Joe S, Kim J, Lee J, Jeon J, Byeon I, Han S
. Epigenetic insights into colorectal cancer: comprehensive genome-wide DNA methylation profiling of 294 patients in Korea. BMB Rep. 2023; 56(10):563-568.
PMC: 10618077.
View
14.
Johnson W, Li C, Rabinovic A
. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2006; 8(1):118-27.
DOI: 10.1093/biostatistics/kxj037.
View
15.
Chen Z, Zhao G, Wang K, Wang X, Ma Y, Xiong S
. Blood leukocytes methylation levels analysis indicate methylated plasma test is a promising tool for colorectal cancer early detection. J Cancer. 2021; 12(12):3678-3685.
PMC: 8120172.
DOI: 10.7150/jca.57114.
View
16.
Al-Sukhni E, Attwood K, Gabriel E, LeVea C, Kanehira K, Nurkin S
. Lymphovascular and perineural invasion are associated with poor prognostic features and outcomes in colorectal cancer: A retrospective cohort study. Int J Surg. 2016; 37:42-49.
DOI: 10.1016/j.ijsu.2016.08.528.
View
17.
Fu T, Liu Y, Li K, Wan W, Pappou E, Iacobuzio-Donahue C
. Tumors with unmethylated MLH1 and the CpG island methylator phenotype are associated with a poor prognosis in stage II colorectal cancer patients. Oncotarget. 2016; 7(52):86480-86489.
PMC: 5349928.
DOI: 10.18632/oncotarget.13441.
View
18.
Esteller M
. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet. 2007; 16 Spec No 1:R50-9.
DOI: 10.1093/hmg/ddm018.
View
19.
Chang E, Park D, Kim Y, Kim B, Park J, Kim H
. Detection of colorectal neoplasm using promoter methylation of ITGA4, SFRP2, and p16 in stool samples: a preliminary report in Korean patients. Hepatogastroenterology. 2010; 57(101):720-7.
View
20.
Noushmehr H, Weisenberger D, Diefes K, Phillips H, Pujara K, Berman B
. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010; 17(5):510-22.
PMC: 2872684.
DOI: 10.1016/j.ccr.2010.03.017.
View